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Abstract
Purpose: We determined whether neoplastic disease,
which was missed under white light can be found during
transurethral resection of bladder cancer by 5-aminole-
vulinic acid-induced porphyrin fluorescence. Materials
and Methods: 5-Aminolevulinic acid-induced fluores-
cence endoscopy was carried out in 328 cases. A 3%
5-aminolevulinic acid solution was instilled intravesically
in a mean time of 2.8 h before endoscopy. The fluores-
cence was excited by a special incoherent light source
which provided blue light in addition to white light.
Results: In 82 (25%) cases additional neoplastic lesions
were found only because of their red porphyrin fluores-
cence which was induced by 5-aminolevulinic acid. 31%
of these neoplastic foci which were found in normal and
nonspecific inflamed mucosa had a poorly differentiated
histology. Conclusions: 5-Aminolevulinic acid facilitates
detection of neoplastic disease during transurethral re-
section of bladder cancer and increases the accuracy of
diagnosis.
Introduction
Flat transitional cell carcinoma with insignificant en-
hancement of the urothelium and neoplastic lesions like
dysplasia or carcinoma in situ without thickening of the
epithelium can easily be missed during transurethral
resection [1]. Thus, methods for in vivo marking of uro-
thelial cancer have been sought [2–5]. We have applied a
method for fluorescence marking of urothelial neoplasia
of the bladder, which is based on intravesical application
of 5-aminolevulinic acid (5-ALA) [6]. 5-ALA is an initial
substrate of the heme biosynthesis. Exogenous applica-
tion of 5-ALA induces an accumulation of fluorescent
porphyrins mainly protoporphyrin IX (PPIX) in tissues of
epithelial origin [7].
Using a krypton ion laser (Ï = 406.7 nm) for fluores-
cence excitation, we have previously reported that the
5-ALA-induced fluorescence is significantly correlated
with neoplastic findings [6], including a low or negative
PPIX fluorescence in adjacent stromal cells, as shown by
fluorescence histology of sections [8]. However, the
spread of the procedure was impaired because of the
large-scale laser technology and the price of 5-ALA. The
krypton ion laser was replaced by a special incoherent
diagnosis light system (D-light, Storz GmbH, Tuttlingen,
Germany). We report on our first clinical experience with
5-ALA-induced fluorescence endoscopy (AFE) for detec-
tion of primary and recurrent bladder cancer using the
D-light.
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Materials and Methods
Patients
A total of 208 patients underwent 328 5-ALA-induced fluorescence
endoscopies. 72 patients were inspected for primary bladder cancer,
and 136 patients were under surveillance because of prior transitional
cell carcinoma of the urinary bladder. The age range of the patients (38
women and 170 men) in which fluorescence endoscopy was carried out
was 16–89 years with an average age of 64.8 years. The number of AFE
per patient ranged from 1 to 7 with a medium of 1.6. The average time
of follow-up was 11.1 months (range 1–29 months).
The patients which were previously treated for bladder cancer
had a history of multiple transurethral resections (range 1–20, aver-
age 3.5) and intravesical instillations with BCG (50 patients) or Mito-
mycin C (49 patients).
5-ALA Administration. 1.5 g of 5-aminolevulinic acid hydro-chlo-
ride (Medac GmbH, Hamburg, Germany) dissolved in 50 ml 1.4%
NaHCO3 was instilled intravesically with a 14F catheter 2–3 h prior
to endoscopy. The catheter was removed immediately after instilla-
tion. The pH value of the solution was 4.9. The solution was freshly
prepared immediately before instillation and passed through a
0.2-Ìm filter to eliminate pyrogens. The individual intravesical
retention ranged from 0.5 to 5.5 h (average 2.8 B 1.4). 12 patients
voided within 1 h after intravesical instillation of the 5-ALA solution
and were excluded from evaluation.
Fluorescence Excitation. The D-light (Storz GmbH) provides
blue light (375–440 nm) for fluorescence excitation of PPIX. A yel-
low longpass filter fit into the eyepiece of the endoscope reduces the
blue excitation light and enhances the fluorescence contrast. In order
to keep the transmission of the blue excitation light minimal the
fiberoptic light cord was integrated into the telescope (30-degree
lens). Switching between blue and white light is possible by means of
a foot pedal.
Fluorescence Endoscopy
In 288 patients, a bladder washing with 100 ml 0.9% sodium
chloride solution was carried out at the beginning of endoscopy
before AFE. In all cases endoscopy started with carefull inspection
under white light. Particular attention was paid, whether tumors
detected with white light during endoscopy showed red fluorescence
under blue-light excitation. The number and location of tumors
under white light were recorded. The endoscopy was continued
under blue excitation light and all and all fluorescing lesions were
documented. Special attention was paid whether these lesions were
detected under white light or not. The procedure went on with resec-
tion of all exophytic lesions by means of a 24F continuous flow endo-
scope (Storz GmbH). In addition, biopsies from fluorescing areas,
which appeared to be normal or nonspecifically inflamed were taken,
and an attempt was made to resect or coagulate these flat lesions.
Also, specimens were obtained with the electrical cutting loop from
suspicious areas which were fluorescence negative. The fluorescence
of the lesions was judged at the extended urinary bladders which
were free of folds. Resection of tumors was carried out with the naked
eye or with support of a special RGB-endocamera (Telecam SL, Storz
GmbH). The controller of the one-chip charge coupled device
camera is equipped with a frame store, enabling target integration. 15
or 8 frames per second were used most frequently. The optical trans-
mission to the red channel had been optimized and the sensitivity
balance of the colors can be performed independently for white light
and blue fluorescence excitation light.
Evaluation of Data
Results of AFE are described in a per patient fashion. Low-grade
dysplasias were judged as benign. If lesions with different gradings
were found the worst diagnosis was taken into account.
Results
Papillary urothelial cancer and carcinoma in situ de-
veloped a brilliant red fluorescence (fig. 1). In contrast,
the adjacent normal nonfluorescent urothelium appeared
blue. In table 1, the results of the 328 AFE are listed. In
159 AFE, neoplastic lesions were resected or biopsied. In
82 AFE, additional dysplastic or malignant urothelium
was found only because of the red PPIX fluorescence. 39
of these 82 AFE had been carried out in patients who were
inspected for primary bladder cancer, whereas 43 cases
had a history of bladder cancer. In 97 AFE only fluoresc-
ing benign biopsies had been taken. 48 AFE were man-
aged without biopsies because of complete fluorescence-
negative findings and normal findings in white light. In
another 20 AFE without papillay tumors, the mucosa of
the bladder was completely red fluorescence-negative.
However, biopsies from suspicious areas under white
light were taken in these. None of these biopsies revealed
neoplastic disease. In 4 patients pTaGI tumors were ob-
served under white light which did not fluoresce in AFE.
Table 2 demonstrates the cases in which only normal
or nonspecific inflammatory lesions were detected at
white light endoscopy. The patients reported in table 3
represent the group which showed exophytic tumors at
white light endoscopy. The sole detection of tumorous
lesions by red PPIX fluorescence in the two groups shown
in tables 2 and 3 can be summed up with the following
numbers: dysplasias were detected in 24 AFE, carcinoma
in situ (CIS) in 22, high-grade papillary TCC was discov-
ered in 4, and papillary lesions of moderate and low dif-
ferentiation in 32 AFE. Of 22 patients with CIS, 16
patients had additional flat dysplastic lesions and 3 pa-
tients showed TaGI–II lesions. In none of the 4 patients
with Ta–1 GIII tumors was CIS found.
In the group of patients without exophytic tumors 29
patients presented a cytology positive or suspicious for
disease. In 14 cases the cytological findings were verified
by AFE detecting the precise site of malignancy within the
bladder. Despite negative cytology, moderate dysplasia,
CIS, high-grade superficial urothelial cancer and low-to-
moderately differentiated superficial cancer were de-
tected in 13, 4, 3 and 11 AFE, respectively, only because
of their red porphyrin fluorescence. 15 patients had a pos-
itive cytology, however, no neoplastic biopsies were found
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Fig. 1. a Endoscopic view of red fluorescing multifocal papillary tumors in contrast to their appearance under white
light. Reduced from !5. b Endoscopic view of a red fluorescing lesion of carcinoma in situ in contrast to its appear-
ance under white light. Reduced from !8.
within the bladder by AFE. In all these cases neoplastic
disease of the upper urinary tract was excluded by a retro-
grade pyelography and washing cytology of the renal pel-
vis. Details on these findings are given in table 4 . In 4 of
13 patients with a cytological diagnosis of moderate dys-
plasia, disease was verified histologically under further
surveillance by AFE-guided biopsies. Two cases with flat
Ta GI–II tumors and two with CIS were found. In 2 pa-
tients cytological diagnosis was high-grade dysplasia. In 1
patient with a follow-up of 10 months, no neoplastic
lesion has been localized so far. In the other patient a
small moderately dysplastic lesion was found 8 months
later by AFE-guided biopsies. Local or systemic side
effects especially cutaneous photosensitization due to the
instillation of 5-ALA and the use of blue light for fluores-
cence excitation were not observed.
a
b
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Positive
Positive
Moderate dysplastic
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Table 1. Final results of the
5-aminolevulinic acid-induced fluorescence
endoscopy findings
AFE
n %
Number of
resected areas
range/average
Result of AFE
23 1–10/2.6 all neoplastic lesions detected were fluorescence positive
but were visible under white light
82 25 1–11/4.1 neoplastic lesions were detected additionally only because
of red PPIX fluorescence signal
97 30 1–7/2.2 all fluorescing lesions biopsied were benign
48 15 0/0 the complete urothelium of the bladder was fluorescence
negative, no biopsies were taken
20 6 1–10/1.5 the complete urothelium of the bladder was fluorescence
negative; all biopsies taken were benign
4 1 1–5/1.9 the complete urothelium of the bladder was fluorescence
negative; additionally fluorescence-negative small
papillary tumors were found
328 100 0–11/2.2 total
Table 2. Detection of additional
neoplasias in flat lesions, solely due to
the positive PPIX fluorescence in patients
with exophytic tumors
Bladder washing
cytology
Total
AFE
AFE with neoplastic disease detected only
because of positive fluorescence
Dys II Cis Ta–1 GIII Ta–1 GI–II
59 4 11 – 17
Negative 88 3 2 2 10
Not done 20 1 – – 3
Table 3. Detection of additional
neoplasias in flat lesions, solely due to
the positive PPIX fluorescence in patients
with normal or nonspecific inflammed
mucosa
Bladder washing
cytology
Total
AFE
AFE with neoplastic disease detected only
because of positive fluorescence
Dys II Cis Ta–1 GIII Ta–1 GI–II
29 6 6 1 1
Negative 112 10 2 1 1
Not done 20 – 1 – –
Table 4. Outcome of 15 patients with
complete fluorescence negative findings
during the initial AFE
Bladder washing
cytology
Patients Follow-up
months
Outcome of patients
NED positive AFE-guided biopsies
Dys II Ta GI–II Cis
13 5–18 9 – 2 2
High-grade dysplastic or
carcinoma in situ 2 8, 10 1 1 – –
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Discussion
The risk of overlooking neoplastic lesions of the blad-
der using white-light endoscopy is significant. After trans-
urethral resection of superficial bladder cancer, tumor
remnants were found in up to 43% of the cases at repeated
resection 1–2 weeks later [9–11]. Even in the case of soli-
tary superficial bladder tumors residual disease was found
in 24% at a second transurethral resection 5 weeks later
[11]. The authors underlined the quality of their first
resection by the fact that the second resection revealed
infiltrative growth in only 2% of the cases. Therefore,
most of this overlooked neoplasms came from positive
margins or heterotopic lesions.
Klän et al. [9] reported on a fractionated resection of
T1 transitionall cell cancer. In 28% of the patients positive
tumor margins were found while residual disease from the
tumor base was not observed in any case. A routine sec-
ond resection was carried out 8–14 days later and re-
vealed residual disease in 50% of the patients despite the
surgical report of complete resection. 76% of the missed
lesions were found to be visible tumors at the repeated
resection. The authors concluded that the extent of the
lesions can easily be misjudged even by experienced sur-
geons. AFE was very helpful in finding residual tumor at
the end of the transurethral resection. Especially the bor-
derline of a tumor was more clearly visible than it was
under white light. Neoplastic lesions in the surroundings
of exophytic tumors which appeared normal or nonspecif-
ically inflamed were marked by brightly shining red PPIX
fluorescence. In the case of multiple tumors, the spots of
neoplastic disease were found more easily and more
promptly by AFE compared to white-light endoscopy
alone.
Fitzpatrick et al. [12] reported on 414 newly diagnosed
patients with pTa GI–II tumors. Patients who underwent
intravesical therapy during their follow-up were excluded
from this study. In one third of the patients recurrent, or
more likely residual, disease was found 3 months after the
initial resection. 90% of these patients had further recur-
rences thereafter, whereas only 21% of the patients who
were free of tumor 3 months after the initial resection
demonstrated recurrent tumor during further follow-up.
The response to the initial treatment of superficial blad-
der cancer for the outcome of the patients has also been
stressed as relevant by Pryor. [13]. Therefore, a complete
removal of tumorous lesions from the bladder seems
advisable. Especially flat lesions as CIS which may be con-
cealed in the nonspecific inflamed or normal-appearing
mucosa are of crucial effect on the rates of progression
and recurrence and require adequate intravesical immu-
notherapy without delay [14–16]. Random biopsies were
found to be an insufficient method for detecting flat
lesions [17, 18]. In a retrospective study Kiemeney et al.
[17] found no correlation between patient outcome where
selected mucosal biopsies were not performed or, if done,
were normal. However, if dysplasia or CIS were found in
patients, they had a statistically significant higher risk of
tumor progression. Therefore, random biopsies seem to
be inadequate since relevant early stage and precancerous
lesions are often missed. Cytology of voided urine or blad-
der washings are valuable for the diagnosis, especially of
high-grade lesions. However, recent prospective trials
have resulted in a disappointingly low sensitivity of 54%
for detecting CIS [19]. Using white-light endoscopy, the
detection of neoplasms is limited to morphological pat-
terns. Since the 1960s, urologists have sought for methods
of in vivo labeling neoplastic lesions in order to decrease
the risk of overlooking tumors by the help of an additional
color contrast.
Methods based on detection of the fluorescence of sys-
temically administered tetracycline, systemic porphyrin
mixtures or fluorescein have only been tested in a few
patients and have been abandonned. Intravesical instilla-
tion of methylene blue was also proven unsuitable, since
70% of CIS and 84% of dysplastic lesions were not stained
[4].
We have been investigating 5-ALA for detection of uro-
thelial cancer since 1991. 5-ALA is a precursor of the heme
biosynthesis and induces an accumulation of fluorescent
endogenous porphyrins, mainly protoporphyrin IX
(PPIX) in tissues of epithelial origin [7]. Following intrave-
sical application of 5-ALA, we could demonstrate a se-
lective accumulation of PPIX in urothelial cancer provid-
ing an intensive color contrast between red fluorescing
malignant lesions and the nonfluorescing normal blue mu-
cosa [6]. Spectral measurements in vivo showed a more
than 10-fold higher intensity of fluorescence of urothelial
cancer in comparison to normal urothelium [20]. Due to
the topical mode of administration of 5-ALA and the fast
metabolism, only minor side effects such as urgency and
alginuresis were observed in 7% of the cases [21, 23].
Initially, a krypton ion laser was used for fluorescence
excitation. Based on a biopsy-related evaluation, we re-
ported a significant increase in sensitivity for the diagno-
sis of neoplastic urothelial lesions such a dysplasia and
CIS as well as for papillary tumors by the additional eval-
uation of the porphyrin fluorescence. In total, the proce-
dure was marked by a sensitivity of 96% and a specificity
of 65% [21].
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The outstanding sensitivity of the procedure was con-
firmed by the investigations of Jichlinski et al. [22]. Using
this method of fluorescence detection they found 47 of 97
foci of carcinoma only by fluorescence markings which
were invisible under white-light observation and conclud-
ed that the sensitivity of the method appears to be twice as
good as conventional white-light cystoscopy. The large-
scale laser technology for excitation of the PPIX fluores-
cence was replaced by the D-light® which is a specially
designed incoherent diagnosis light system. This equip-
ment meets all the requirements for a daily routine proce-
dure and can be used in combination with standard uro-
logical endoscopes. Based on a per patient fashion, we
found that the patients had a benefit in 150 of 328 AFE
cases (45%). In 82 cystoscopies additional neoplastic
lesions were found which would have been missed under
white-light observation alone. In 68 cases of complete flu-
orescence negative mucosa no biopsies would have been
necessary due to the high sensitivity of the procedure.
31% of the malignant foci which were found only because
of their positive PPIX fluorescence signal in the normal-
appearing or nonspecific inflamed mucosa were high-risk
lesions such as carcinoma in situ or poorly differentiated
papillary tumors. In 30% of the AFE, exclusively false-
positive findings were observed. This seems to be accepta-
ble as in total the mean number of biopsies was low with
2.2 per patient. No matter how, it is obviously significant-
ly less than the number of random biopsies carried out
under white light. False-positive responses were frequent-
ly found in lesions with increased cellular proliferation
due to inflammation or scarring. However, these lesions
apparently showed a lower fluorescence intensity. There-
fore, methods for fluorescence quantification have been
established and are now under investigation in order to
reduce the rate of false-positive biopsies [24]. Further,
false-positive lesions as simple hyperplasias have shown
to already have genetic changes identical to those of papil-
lary tumors of the same patient [25]. This result indicates
that at least part of the false-positive lesions are tumor
precursors and is investigated intensively in longitudinal
and horizontal studies of patient material.
There is a bad correlation between cytology and AFE.
However, cytology and AFE are not competitive methods
as cytology is a noninvasive and AFE is an invasive proce-
dure. AFE can help clarify suspicious cytological findings
and therefore AFE-guided biopsies and cytology seem to
be complementary methods for accurate diagnosis of
bladder cancer. In 14 of 112 patients who had no exophyt-
ic tumors and had a negative cytology, a neoplastic lesion
was found in fluorescing areas of the bladder wall. In 5 of
15 patients with complete negative fluorescing mucosa
but positive cytology, neoplastic disease was found later
due to positive AFE-guided biopsies during follow-up of
these patients.
Conclusions
5-Aminolevulinic acid-based fluorescence endoscopy facilitates
detection of neoplastic lesions within the bladder during transure-
thral resection. In case of complete negative fluorescence findings,
endoscopy can be done without biopsies due to the high sensitivity of
the procedure. A decrease of the rate of overlooked tumors is
expected for transurethral resection supported by 5-aminolevulinic
acid-induced fluorescence endoscopy. A resulting relatively de-
creased number of recurrences has to be documented in prospective
randomized trials.
Acknowledgement
Supported by grants from the Deutsche Forschungsgemeinschaft
(DFG No. Kr1645/1–1).
References
1 Soloway MS, Murphy W, Rao MK, Cox C:
Serial multiple-site biopsies in patients with
bladder cancer. J Urol 1978;120:57–59.
2 Whitmore WF Jr, Bush IM: Ultraviolet cystos-
copy in patients with bladder cancer. Trans Am
Assoc Genitourin Surg 1965;57:149–155.
3 Jocham D, Baumgartner R, Fuchs N, Lenz H,
Stepp H, Unsöld E: Fluorescence diagnosis of
porphyrin-marked urothelial tumors: Status of
experimental development. Urologe [A] 1989;
28:59–64.
4 Vicente J, Chechile G, Algaba F: Value of in
vivo mucosa-staining test with methylene blue
in the diagnosis of pretumoral and tumoral
lesions of the bladder. Eur Urol 1987;13:15–
16.
5 Zimmern PE, Laub D, Leach GE: Fluorescein
angiography of the bladder: technique and rele-
vance to bladder cancer and interstitial cystitis
patients. J Urol 1995;154:62–65.
6 Kriegmaier M, Baumgartner R, Knuechel R,
Steinbach P, Ehsan A, Lumper W, Hofstaedter
F, Hofstetter A: Fluorescence photodetection
of neoplastic urothelial lesions following in-
travesical instillation of 5-aminolevulinic acid.
Urology 1994;44:836–841.
7 Kennedy JC, Pottier RH: Endogenous proto-
porphyrin IX; a clinically useful photosensitiz-
er for photodynamic therapy. J Photochem
Photobiol [B] 1992;14:275–292.
392 Eur Urol 1999;36:386–392 Kriegmair/Zaak/Stepp/Stepp/Baumgartner/
Knuechel/Hofstetter
8 Steinbach P, Kriegmaier M, Baumgartner R,
Hofstaedter F, Knuechel R: Intravesical instil-
lation of 5-aminolevulinic acid: the fluorescent
metabolite is limited to urothelial cells. Urolo-
gy 1994;44:676–681.
9 Klän R, Loy V, Huland H: Residual tumor dis-
covered in routine second transurethral resec-
tion in patients with stage T1 transitional cell
carcinoma of the bladder. J Urol 1991;146:
316–318.
10 Vögeli TA, Grimm MO, Ackermann R: Pro-
spective study for quality control of TUR of
bladder tumors by routine 2nd TUR. J Urol
1998;159(suppl):143.
11 Köhrmann KU, Woeste M, Kappes J, Rass-
weiler J, Alken P: Der Wert der transurethralen
Nachresektion beim oberflächlichen Harnbla-
senkarzinom. Akt Urol 1994;25:208–213.
12 Fitzpatrick JM, West AB, Butler MR, Lane V,
O’Flynn JD: Superficial bladder tumors (stage
pTa, grades 1 and 2): The importance of recur-
rence pattern following initial resection. J Urol
1986;135:920–922.
13 Pryor JP: Factors influencing the survival of
patients with transitional cell tumours of the
urinary bladder. Br J Urol 1973;45:586–592.
14 Smith G, Elton RA, Beynon LL, Newsam JE,
Chisholm GD, Hargreave TB: Prognostic sig-
nificance of biopsy results of normal-looking
mucosa in cases of superficial bladder cancer.
Br J Urol 1983;55:665–669.
15 Heney NM, Ahmed S, Flanagan MJ, Frable W,
Corder MP, Hafermann MD, Hawkins IR: Su-
perficial bladder cancer: progression and recur-
rence. J Urol 1983;130:1083–1086.
16 Flamm J, Dona S: The significance of bladder
quadrant biopsies in patients with primary su-
perficial bladder carcinoma. Eur Urol 1989;2:
81–85.
17 Kiemeney LA, Witjes JA, Heijbroek RP, Ver-
beek AL, Debryune FM: Predictability of re-
current and progressive disease in individual
patients with primary superficial bladder can-
cer. J Urol 1993;150:60–64.
18 Kiemeney LA, Witjes JA, Heijbroek RP, Ko-
per NP, Verbeek AL, Debruyne FM: Should
random urothelial biopsies be taken from pa-
tients with primary superficial bladder cancer?
A decision analysis. Members of the Dutch
South-East Co-Operative Urological Group. Br
J Urol 1994;73:164–171.
19 Sarosdy MF, deVere White RW, Soloway MS,
Sheinfeld J, Hudson MA, Schellhammer PF,
Jarowenko MV, Adams G, Blumenstein BA:
Results of a multicenter trial using the BTA test
to monitor for and diagnose recurrent bladder
cancer. J Urol 1995;154:379–384.
20 Kriegmair M, Stepp H, Steinbach P, Lumper
W, Ehsan A, Stepp HG, Rick K, Baumgartner
R, Hofstetter A: Fluorescence cystoscopy fol-
lowing intravesical instillation of 5-aminolevu-
linic acid: A new procedure with high sensitivi-
ty for detection of hardly visible urothelial neo-
plasias. Urol Int 1995;55:190–196.
21 Kriegmair M, Baumgartner R, Knuchel R,
Stepp H, Hofstaedter F, Hofstetter A. Detec-
tion of early bladder cancer by 5-aminolevu-
linic acid induced porphyrin fluorescence. J
Urol 1996;155:105–110.
22 Jichlinski P, Forrer M, Mizeret J, Glanzmann
T, Braichotte D, Wagnieres G, Zimmer G,
Guillou L, Schmidlin F, Graber P, van den
Bergh H, Leisinger HJ: Clinical evaluation of a
method for detecting superficial surgical transi-
tional cell carcinoma of the bladder by light-
induced fluorescence of protoporphyrin IX fol-
lowing the topical application of 5-aminolevu-
linic acid: Preliminary results. Lasers Surg Med
1997;20:402–408.
23 Rick K, Sroka R, Stepp H, Kriegmair M, Hu-
ber RM, Jacob K, Baumgartner R: Pharmaco-
kinetics of 5-aminolevulinic acid induced pro-
toporphyrin IX in skin and blood. J Photochem
Photobiol [B] 1997;40:313–319.
24 Kriegmair M, Wagner S, Stepp H, Hofstetter
A: Fluoreszenzquantifizierung bei der 5-Ami-
nolävulinsäure induzierten Fluoreszenzendos-
kopie des Harnblasenkarzinoms. Urologe [A]
1997;37:S50.
25 Knuechel R, Kutz H, Hofstaedter F, Hofstetter
A, Kriegmair M: Photodynamic diagnostics
with 5-ALA in bladder cancer: Biology of false
positive lesions. Urol Res 1997;25:94–95.
